Original Article

Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma

Abstract

Background: We aimed to evaluate the whether AFP levels alone is an adequate screening indicator, or a combination of Generally, alpha-fetoprotein (AFP), CA19-9 and CEA could provide a better diagnostic tool in detecting and screening asymptomatic patients with primary hepatic cancer (PHC), and also evaluate the correlation of degree of differentiation with serum biomarker levels.

Methods: We retrospectively reviewed the medical records of 1362 patients form 2014-2018 who visited the first Affiliated Hospital of Zhejiang University, Hangzhou, China for health check-ups or were diagnosed with cancer or cirrhosis. We then analyzed preoperative tumor markers level of AFP, CA19-9, and CEA. The standard reference values (AFP ≤20 ng/L CEA ≤ 5 ng/L, and CA19-9  ≤ 37 U/mL) were as positive or negative cut off values. Further, the histological sections of patients were categorized and correlated them with the three serum biomarkers.

Results: Serum AFP, CEA, and CA19-9 levels in the PHC group were significantly higher compared to those with liver cirrhosis and healthy control groups (P < 0.03). With AFP as a single tumor marker for PHC diagnosis, it had a sensitivity of 63.3% with a specificity of 80.8%. AFP combined with CA19-9 and CEA showed specificity of 100%, a sensitivity 2.5% with the positive and negative predictive values of 100% and 22% respectively. Furthermore, histological evaluation revealed the highest AFP level of 9366.14±23902.61 ng/L associated with poorly differentiated HCC, while well-differentiated HCC, had the lowest mean AFP level of 45.19±181.27 ng/L.

Conclusion: Combined serum levels of AFP, CA19-9  and CEA does not provide a superior advantage over AFP alone as a screening and diagnostic tool for HCC detection.

 

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65:87-108.
2. Yuen MF, Hou JL, Chutaputti A (2009). Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol, 24:346-353.
3. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma (2010). Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol, 25:657-663.
4. Song P, Feng X, Zhang K et al. (2013). Perspectives on using des-gamma-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr,2:227-231.
5. Chinese Anti-Cancer Association Society of Liver Cancer, Chinese Society of Clinical Oncology, Chinese Society of Hepatology Liver Cancer Study Group. The expert consensus on the treatment standards for hepatocellular carcinoma. Digestive Disease and Endoscopy 2009. (in Chinese)
6. Tanaka M, Katayama F, Kato H et al. (2011). Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol, 21:401-416.
7. Kudo M, Han KH, Kokudo N et al.(2009). Liver Cancer Working Group report. Jpn J Clin Oncol,40 Suppl 1:i19-27.
8. Song P, Feng X, Zhang K et al.(2013). Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends,7:1-6.
9. Zhang C, Zhong Y, Guo L (2013). Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. Biosci Trends,7:7-12.
10. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S (1994). Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology,19:61-66.
11. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E (1996). Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer,78:977-985.
12. Anonymus (1998). A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 28:751-755.
13. Siegel RL, Miller KD, Jemal A (2018). Cancer statistics 2018. CA Cancer Statistics, 68(1):7-30.
14. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379:1245-1255.
15. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. (2005). Management of hepatocellular carcinoma. Hepatology, 42:1208-1236.
16. Llovet JM, Bustamante J, Castells A et al. (1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29:62-67.
17. Song P, Tobe RG, Inagaki Y et al. (2012). The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int, 32:1053-1063.
18. Song P1, Gao J, Inagaki Y et al (2013). Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. Liver Cancer, 2(1):31-9.
19. Aghoram R, Cai P, Dickinson JA (2012). Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev, Cd002799.
20. Amarapurkar D, Han KH, Chan HL, Ueno Y; Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma (2009). Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol, 24:955-961.
21. El-Serag HB, Kanwal F (2014). Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology, 60:1767-1775.
22. American Cancer Society (2015). Cancer Facts And Figures. Atlanta, Ga. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
23. Trevisani F, D'Intino PE, Morselli-Labate AM et al.(2001). Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol,34:570-575.
24. Khien VV, Mao HV, Chinh TT et al. (2001). Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers,16:105-111.
25. Yoshida S, Kurokohchi K, Arima K et al (2002). Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol, 20:305-309.
26. Daniele B, Bencivenga A, Megna AS, Tinessa V (2004). Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology,127:S108-112.
27. Farinati F, Marino D, De Giorgio M et al. (2006). Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol,101:524-532.
28. Johnson PJ (2001). The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis, 5:145-159.
Files
IssueVol 48 No 2 (2019) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v48i2.830
Keywords
Hepatocellular carcinoma Primary hepatic cancer Serum Biomarkers Alpha fetoprotein Carci-noembryonic antigen Cancer antigen 199
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
EDOO MIA, Chutturghoon VK, WUSU-ANSAH GK, ZHU H, ZHEN TY, XIE HY, ZHENG S-S. Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma. Iran J Public Health. 2019;48(2):314-322.